CNBC’s “Fast Money” team discusses the stock charts of two AI companies and their strategies for trading in the space. San Antonio man beat 12-year-old son to death. Here's his prison sentence.

CNBC’s “Fast Money” team discusses Trump announcement of a new tariff of 100% on imports from China, the market reaction and more. How China reacted to "No Kings" anti-Trump protest in US At the 2025 ...

Your old smartphones and laptops—collecting dust in a drawer—contain a valuable metal that many companies are desperate to reclaim. Copper is an essential commodity that fuels electrical ...

Funding is available to fast-track permits for projects that meet Trump administration priorities, despite the government shutdown, Emily Domenech, executive director of the Federal Permitting ...

They have direct deposit like a lot of U.S. workers, but some don’t get paid on a biweekly basis. I'm curious about how the president and members of Congress get paid. Do they get a paycheck every ...

Could you get part of the $177 million that AT&T will pay customers soon? The checks are a settlement in a class-action lawsuit that alleged customer data was breached multiple times last year. One ...

A $2.5 billion settlement between the Federal Trade Commission and Amazon over its Prime program could put money back in your pocket in the coming months. The agency alleged that the retail giant used ...

A downtown Los Angeles company and two executives are facing multi-million-dollar fines and prison time after being convicted of money laundering and evading customs duties and taxes. C’est Toi Jeans ...

What’s the difference between Meta Platforms and OpenAI? The big one – and perhaps the most important one in the long run – is that when Meta Platforms does a deal with neocloud CoreWeave, it actually ...

Tyreek Hill is under contract through 2026 with a potential out after this season. Hill is due to make $36 million in 2026 with a salary cap hit worth $52 million and a dead cap value of $28.2 million ...

Analysts at JMP Securities have reaffirmed their ‘Market Outperform’ rating on Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), while raising the price target to $143 from $86, implying an upside ...